UBS AM’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
SL
UBS AM's GPCR Position: Q3 2026 in Review
UBS AM opened a new position in Structure Therapeutics (GPCR) in Q3 2026: 30 shares worth $938. The stake represents ﹤0.01% of the portfolio and ranks #4133 among its holdings. This is a return to the name: UBS AM previously reported a position in GPCR as recently as Q2 2025.
UBS AM first reported a position in GPCR in Q1 2025 and has held it in 3 quarters since. The position peaked at $102K in Q1 2025. 132 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- UBS AM held 30 shares of Structure Therapeutics worth $938 as of Q3 2026.
- Structure Therapeutics was a new UBS AM position in Q3 2026.
- Structure Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4133 holding.
- UBS AM first reported a position in Structure Therapeutics in Q1 2025 and has held it in 3 quarters since.
- UBS AM's Structure Therapeutics position peaked at $102K in Q1 2025.
- 132 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.